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Opinion statement
Influenza management and surveillance programs in Japan possess several unique fea-
tures. The national influenza surveillance is affiliated with National Epidemiological
Surveillance for Infectious Diseases (NESID) and features sentinel outpatient surveillance,
virological surveillance, and reports on hospitalization, mortality, and influenza-
associated encephalopathy. Of note, information on the number of student absences
and class/grade/school closures due to influenza are also reported to the government
and made publically available. A private online influenza surveillance portal by volunteer
doctors provides a real-time information source for the Japanese clinicians and the
general public. For influenza treatment, three classes of drugs are approved and covered
by national medical insurance in Japan: M2 inhibitors, neuraminidase inhibitors (NAIs),
and a polymerase inhibitor. Four NAIs, oseltamivir, zanamivir, laninamivir, and peramivir,
are licensed in Japan and are prescribed to seven to eight million patients annually. NAIs
are prescribed to any influenza outpatient rather than being limited to severe cases. The
majority (80–95 %) of patients start the treatment within 48 h of onset. Laninamivir and
peramivir were used almost solely in Japan, until the approval of the latter drug by the
FDA. Observational studies showed that the two drugs have equal effectiveness as
oseltamivir and zanamivir. The Japanese approach to influenza surveillance and manage-
ment has facilitated bringing new influenza antivirals to the markets and has driven
innovative research in this field. New classes of antivirals, including polymerase inhibitors
and cap-dependent endonuclease inhibitor, provide novel tools for treatment of influenza
in Japan and the rest of the world.
* The Author(s) 2016. This article is published with open access at Springerlink.com
Introduction
Influenza is a highly transmissible viral infection associated
with serious public health and economic issues. Each year,
various strains of influenza viruses circulate throughout the
world and cause significant morbidity and mortality [1].
So far, three types and subtypes of influenza virus, influ-
enza A (H1N1) pandemic 2009 (pdm09), A(H3N2), and
B are mainly associated with human infections [2]. Effec-
tive surveillance andmonitoring of influenzaoutbreaks are
critical for evaluating the impact of the disease on the
community and for devising diseasemanagement policies.
Japan has robust and unique national influenza surveil-
lance systems comprising of countrywide, sentinel-based
surveillance of influenza-like illness (ILI), viral surveillance,
number of school absences, and excess mortality.
Vaccination is the most important measure for pre-
vention of seasonal influenza, while antiviral drugs pro-
vide the cornerstone for early outbreak response in case
of a pandemic [3]. Three neuraminidase inhibitors
(NAIs) are currently licensed worldwide for treatment
and prophylaxis of influenza infections: oseltamivir
(Tamiflu®, Hoffmann-La Roche), zanamivir (Relenza®,
GlaxoSmithKline), and peramivir (Rapiacta®, Shionogi
or Rapivab, BioCryst) [4, 5•]. In addition to these three
NAIs, laninamivir (Inavir®, Daiichi Sankyo) is exclusive-
ly available in Japan for influenza treatment and pro-
phylaxis [6, 7]. Recently, Japan also approved a poly-
merase inhibitor, favipiravir (Avigan®), for treatment of
influenza [8•, 9].
Japan is the one of top consumers of NAIs in the
world [3, 6, 10, 11]. In recent years, the USA became the
highest consumer of oseltamivir followed by Japan.
During January to December 2014, Japan comprised
11.8 % of global sales, with the USA being the highest
(71.5 %), Europe the third (7.7 %), and the rest of the
world (9.0 %), according to the Media Release from F.
Hoffmann-La Roche Ltd. [12].
In this review, we focus on the unique national in-
fluenza surveillance and clinical management and usage
of neuraminidase inhibitors, such as laninamivir and
peramivir that are not widely used in other countries.
We also review new classes of anti-influenza drugs in-
cluding favipiravir and S-033188.
National Influenza Surveillance
Outpatient Surveillance of Influenza-Like Illness
The infectious disease surveillance program in Japan, initiated in 1981, formed
the basis for influenza surveillance for outpatients [13, 14]. This program was
revised and updated to its present form following the revision of the Infectious
Disease Control Law in 1999 [13–16]. The system is currently called National
Epidemiological Surveillance for Infectious Diseases (NESID), which includes a
mandatory reporting system for nationally notifiable diseases and sentinel
surveillance systems for various kinds of infectious diseases [17].
Influenza falls under the sentinel surveillance arm of the program. Weekly
numbers of influenza patients are reported from 5000 medical institutions
nationwide to local health centers. Sentinel sites were designated according to
their geographic distribution, type of medical institutions (clinic or hospital),
and population densities. These sentinels use the following criteria for reporting
ILI: (1) sudden onset of illness, (2) fever 938 °C, (3) symptoms of upper
respiratory inflammation, and (4) systemic symptoms such as general fatigue. A
case is considered to meet the reporting criteria if the patient meets all symp-
toms from (1) to (4) or with at least one of the symptoms combined with a
positive rapid diagnostic test (RDT) [17]. Sentinel sites report the age group and
sex of patients on a weekly basis. The report does not include personal infor-
mation like names or addresses. This information is transferred from local
health centers to the prefectural government where it is aggregated into a
prefectural report. The report is then forwarded to the National Institute of
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Infectious Diseases (NIID) in Tokyo, which is affiliated to the Ministry of
Health, Labour and Welfare (MHLW). Major cities report directly to NIID
without going through the prefectural government. The data is aggregated at
NIID into a weekly total number of cases and number of visits per medical
institution at prefectural level. The surveillance reports are released on a weekly
basis on the website of the Infectious Disease Weekly Report (http://www.nih.
go.jp/niid/en/idwr-e.html).
Estimates fromNESID data showed that the numbers of ILI cases presenting
as outpatients during the 2009 pandemic and the four post-pandemic seasons
(2009/2010, 2010/2011, 2011/2012, 2012/2013, and 2013/2014) were 20.9,
13.9, 16.8, 13.8, and 15.4 million, respectively [13, 14, 18]. It was estimated
that almost 20 % of Japanese population was infected with the influenza
A(H1N1)pdm09 at the start of pandemic in 2009, but this figure subsequently
decreased in the following seasons.
Virological Surveillance
Virological surveillance, consisting of testing for influenza virus and the analysis
of viral antigenicity, is incorporated into outpatient surveillance under the
scheme of NESID. Around 500 medical institutions out of 5000 sentinel sites
are designated as pathogen collection sites [14]. Clinicians in the community
routinely take nasopharyngeal swabs from ILI patients and send the samples to
local (prefectural or municipal) public health laboratories. Currently, 81 public
health laboratories are located in major municipalities and all 47 prefectures.
Those public health laboratories are in charge of detecting influenza virus by
isolation and PCR testing (a list of laboratories is available from web site of the
Japan Association of Prefectural and Municipal Public Health Institute, URL at
http://www.chieiken.gr.jp/, in Japanese only).
After initial typing and subtyping is performed, selected strains are sent to
NIID for further analysis to be used for vaccine selection. Countrywide data
including virus type and subtype is tabulated at NIID and made publicly
available under the Infectious Agent Surveillance Report (IASR, http://www.nih.
go.jp/niid/ja/iasr-inf.html). Around 6000–8000 influenza viruses are isolated
annually in Japan. By combining ILI (NESID) and virological surveillance data,
influenza type and subtype-specific [i.e., A(H1N1)pdm09, A(H3N2), and B]
prevalence can be estimated [14].
Influenza-Associated Hospitalizations
In addition to outpatient and virological surveillance, data on the number of
influenza-associated hospitalizations is also collected under NESID. Around
500 hospitals nationwide possessing more than 300 beds are selected as senti-
nels. Reporting on hospitalization started in 2011. During the pandemic in
2009, physicians had to report all hospitalized cases with confirmed influenza
A and influenza B via the internet-based National Epidemiological Surveillance
of Infectious Diseases (iNESID). This web-based data collection system was
made available only from July 24 to September 5, 2009 [16]. Data obtained
from iNESID revealed that the overall hospitalization rate for influenza
A(H1N1)pdm09 infection was 5.8 cases per 100,000 population; cases hospi-
talized for non-therapeutic purposes, such as mere quarantine, were excluded.
The figure is almost one fourth of that which was reported from Australia and
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the USA [16], supporting the lower frequency of severe illness in Japan during
the pandemic compared to other countries. So far, the NESID data on nation-
wide hospitalization rate of influenza after the first wave of the 2009 pandemic
has not been published.
Influenza-Associated Encephalopathy and Mortality
Influenza-associated encephalopathy (IAE) is an acute encephalopathy caused by
influenza virus infection. IAE has been reported in Japan since late 1990s [19]. It
is the leading cause of deaths associated with influenza infections among chil-
dren in Japan. Nationwide reports on IAE started under the diseases entity of
Bacute encephalitis (AE)^ since November 2003 under the NESID surveillance
[20]. Case definitions of the IAE include (1) a positive result on viral culture, viral
antigen testing, or viral ribonucleic acid polymerase chain reaction in respiratory
specimens (or any organs) or a fourfold or greater rise in paired serum antibody
titer test (hemagglutination inhibition or complement fixation test); (2) neuro-
logical signs and symptoms showing impaired consciousness, seizures, and
abnormal behaviors and/or cognition. Impaired consciousness is defined as
equal to or below 13 on the Glasgow Coma Scale. Abnormal behaviors and
cognition are jumping from heights, hallucination, delirium, and agitation. In
some cases, signs of increased intracranial pressure are observed, such as nausea,
papillary edema, low blood pressure, abnormal ocular movement, or postures.
These symptoms should persist for more than 24 h [21–24]; (3) abnormal brain
CT or MRI findings that suggest mild encephalitis/encephalopathy with a re-
versible splenial lesion (MERS), one posterior reversible encephalopathy syn-
drome, and one diffuse swelling of the cerebrum and high signal areas in several
regions of white or gray matter by diffusion-weighted image (DWI) or fluid-
attenuated inversion recovery (FLAIR) [23].
Note that the detection of influenza virus from CSF is not required for a
diagnosis of IAE in the Japanese guidelines because it has been shown that the
influenza virus and inflammatory cells are not always detectable in the CSF of
such patients, but they must have detectable influenza virus in their respiratory
tract, and no other causes were found for this presentation [22•, 25–27].
The number of IAE cases increased by 6.9-fold during the 2009 pandemic
compared to the previous seasons [28]. Of the 331 IAE cases reported in the year,
322 (97.2 %) were linked to influenza A(H1N1)pdm09 infection. The case
fatality rate of IAE was 3.7 %, which was lower than that of influenza A- and B-
associated encephalopathy reported in the previous seasons (12.9 and 14.0 %,
respectively) [28].
Official records of the Ministry of Health, Labour and Welfare indicate 199
influenza-related deaths during the first wave of the 2009 pandemic (i.e.,
May 2009–May 2010) [29]. Themortality rate in Japan during the pandemic was
estimated at 0.16 per 100,000 and is lower than that reported in other countries,
such as the USA (3.96 per 100,000), Canada (1.32 per 100,000), Mexico (0.93
per 100,000), Australia (0.93 per 100,000), the UK (0.76 per 100,000), Singa-
pore (0.57 per 100,000), Korea (0.53 per 100,000), and France (0.51 per
100,000) [29]. The variation in influenza mortality rates in different countries
might be partly attributed to differences in the reporting systems and case
definition in each country. However, overall these figures suggest lowermortality
rate during the pandemic in Japan [30].
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Sugaya reported that overall number of pediatric deaths during the first wave
of the 2009 pandemic caused by the emergence of influenza A(H1N1)pdm09
virus was 38 among children 15 years old and under [31]. This is lower than the
reported mortality figures for this age group during 2004–2008. It showed the
pediatric deaths did not increase in Japan, in contrast to other countries such as
the USA, which had a pediatric death rate several times higher in 2009.
The lower incidence of severe illness and lowermortality rates in Japan during
the 2009 pandemic are believed to be a result of universal implementation of
early treatment withNAIs in the community clinics [30, 31]. Early treatment with
NAIs was more widely and more thoroughly implemented during the 2009
pandemic than ever before. A study of 1000 children hospitalized because of
A(H1N1)pdm09 infection revealed that NAIs, primarily oseltamivir, had been
used to treat 984 (98.4 %) of the 1000 patients [31]. Of note, 88.9 % (593/667)
of the patients for whom accurate data were available, treatment with NAIs was
initiated within 48 h after the onset of illness, and 69.9 % (466/667) of patients
started treatment within 24 h after the onset of illness.
Student Absence and School Closure Surveillance
Surveillance for student absence and school closures is a very unique feature of
the Japanese influenza surveillance and public health intervention system. The
School Health Act enacted in 1958 in Japan contains various regulations on
school safety and hygiene [32]. The School Health and Safety Act in Japan states
that children with influenza infection should stay home for at least 6 days after
symptomonset [33]. The same act designates that the schoolmasters can decide
whether to close the class, grade, or school depending on the size of outbreaks.
The purpose of this regulation is to stop transmitting influenza among
children and to minimize size of outbreaks at schools. This rule is applied not
only to elementary schools but also to children’s day care centers, nursing
schools, junior high schools, and high schools. Then those schools must report
the number of absent students diagnosed with influenza as well as closures
(class, grade, or school) to the local Education Board in each municipality [34].
The information is sent to the Ministry of Health, Welfare and Science, and
the data is aggregated and released on the NIID website divided by prefectural
or major city levels on a weekly basis (http://www.nih.go.jp/niid/ja/flu-flulike.
html). Japanese class closure is generally a reactive measure. There is no na-
tionwide uniform regulation on when to start class closures. It is up to school
masters and the local Educational Board when to close, so the situation differs
by school or area. In many cases, a class is closed when the number of absences
due to ILI exceeds 10–20 %. Several groups evaluated the most optimal dura-
tion of class closure, and it was suggested that school closure lasting more than
4 or 5 days is effective to mitigate the spread of influenza [34–37].
Volunteer-Based Web ILI Surveillance
In addition to surveillance by the public sector, there is a unique web-based
outpatient surveillance, called ML-Influenza Database (http://ml-flu.children.
jp/) [38]. This surveillance is organized by volunteer clinicians and allow real-
timemonitoring of ILI cases at outpatient clinics at a prefectural level. Currently,
more than 200 doctors nationwide post the number of influenza patients
diagnosed at their clinics or practice settings everyday through theML-Influenza
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Database. The data is automatically updated and reflected on the web server.
Site visitors can access nationwide influenza case numbers reported daily and
the map with the ability to zoom in to city level.
A strong correlation (correlation coefficient = 0.81–0.99) has been demon-
strated between the weekly number of ILI reported by NESID and that by ML-
Influenza Database, indicating the high validity and usefulness of this
volunteer-based surveillance [38]. Additional information such as influenza
type screened by RDT, age group, male/female ratio, name of the RDT kit used,
the anti-influenza drug prescribed, and the vaccination status of influenza
patients are also available on the website. Since its launch in the 2000–2001
season, the ML-Influenza Database has been quite informative for clinicians
and the general population as it allows real-time monitoring of influenza
trends.
Treatment of Influenza
Three classes of antivirals, M2 inhibitors, NAIs, and a RNA polymerase inhib-
itor, are approved and covered by national medical insurance in Japan. The M2
inhibitor, amantadine (Symmetrel®) is effective only for influenza A. However,
the dug is rarely used in Japan in recent years because of the universal resistance
among influenza A(H1N1)pdm09 and A(H3N2) attributed to an amino acid
mutation serine to asparagine at position 31 in the M2 protein [39–42]. Thus,
NAIs, which are effective against both influenza A and B, are now the drugs of
choice for clinicians [3, 41] A newly developed RNA polymerase inhibitor,
favipiravir (Avigan®), was approved in Japan in 2014, but the use is highly
restricted due to its potential adverse effects [7, 9, 43].
Treatment Guidelines for Outpatients
In terms of NAIs, four drugs are approved in Japan: oseltamivir (Tamiflu®),
zanamivir (Relenza®), peramivir (Rapiacta®), and laninamivir (Inavir®).
Zanamivir was approved in 1999, oseltamivir in 2000, and peramivir and
laninamivir in 2010 [6]. Prescription of an NAI is approved to outpatients
without any comorbidities, as well as to high-risk patients with multiple co-
morbidities.
Oseltamivir is administered orally for 5 days (2 × 75 mg/day for adults and
children weighing 937.5 kg and 2 mg/kg/day for children G37.5 kg) (Table 1)
[44, 45]. Zanamivir is administered by inhalation by patients daily for 5 days
(2 × 10 mg/day for adults and for children ≥5 years) [46]. Laninamivir is
administered by inhalation to adults and to children aged ≥10 years as a single
dose of 40 mg (two devices) and to children G10 years old as single dose of
20 mg (one device), respectively [47]. Peramivir is intravenously infused once
over a period of 15–30 min to infected adults at a dose of 300 mg and to
children at 10 mg/kg as outpatients [48].
In Japan, governmental guidelines are not published but are rather
included in the drug insert. The package inserts are frequently updated
and describe detailed recommendations under the supervision of MHLW.
To supplement package inserts, several academic societies, such as Japa-
nese Association for Infectious Diseases [49], Japanese Society of Che-
motherapy, Japan Pediatric Society, Japanese Respiratory Society, etc.,
issue recommendations and guidelines for the treatment of influenza for
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their specific group of patients. These guidelines are complementary of
the governmental guidelines.
This approach to outpatient care for influenza is completely different from
the situation in the European Union or the USA, where NAIs are mostly
recommended for the higher risk groups (young children, elderly, or individ-
uals of any agewith underlying chronic illness) or residents of nursing homes or
other long-term care facilities at risk of severe disease [4, 50].
The NAIs are generally effective when the treatment is initiated within the
first 48–72 h after symptom onset [51–53]. In Japan, most of ambulatory
patients start NAI treatment within 1–2 days of influenza onset. Studies have
shown that 80–95%of influenza patients in Japan visit amedical facility within
48 h of onset and started the treatment [54, 55]. Other studies have shown that
earlier initiation of antiviral therapy is associated with improved clinical outcomes
in all populations [52, 56–58].
Normally, NAIs are prescribed when an influenza RDT is shown to be positive
[6]. The cost of the RDT is covered by national health insurance, which contributes
to its widespread use. As of 2016, more than 20 kinds of RDTwere available in the
Japanese market. Clinicians can prescribe NAIs even if the RDT shows a negative
result. The choice ofwhichNAI to prescribe is solely up to the clinician and patient,
except in the case of oseltamivir, where age restrictions do exist [7, 49, 59•].
Oseltamivir is not recommended for use to those aged 10 to 19 years old by the
order of MHLW [60], following reports of abnormal behavior in teenagers after
administration in 2007 [59•].
Treatment Guidelines for Hospitalized Patients
Treatment with the NAIs is recommended for influenza patients who require
hospital admission and are as follows: (1) life-threatening, complicated pro-
gressive illness: oseltamivir 75 mg twice daily for 5 days (excluding those aged
10–19 years old) or peramivir one 600-mg dose (repeated administration is
allowed); (2) viral pneumonia: oseltamivir 75 mg twice daily for 5 days (ex-
cluding those aged 10–19 years old) or peramivir single 300-mg dose (600 mg
per infusion when a patient is in severe condition and repeated administration
is allowed); and (3) where illness is not life threatening and without the
complication of pneumonia, all four NAIs are equally recommended. The
dosage and duration of medication are the same as for influenza outpatients
[49]. In general, peramivir is likely to be administered in severely ill patients or
those who have complications because the concentration of the drug in blood is
high and serial injections are possible [61].
Numbers of NAI Doses Prescribed in Japan
Post-marketing surveys by the four manufacturers of NAIs, Chugai Pharma-
ceuticals, GlaxoSmithKline, Daiichi Sankyo, and Shionogi, were reported to the
Ministry of Health, Labour and Welfare, allowing estimation of the number of
NAI prescriptions between 2011 and 2015 influenza seasons [62–65].
During the four influenza seasons, NAIs were prescribed to seven to eight
million patients each year. Thus, more than half of influenza patients in Japan
received NAIs. A vaccine effectiveness study revealed that 96 % of the influenza
patients had received a prescription of NAI [54]. This data shows that prescrip-
tions of anti-influenza agents are very common in Japan. Among the four
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agents, prescriptions of oseltamivir and laninamivir were the highest, with the
two drugs accounting for 70–80 % of all NAIs (Fig. 1) [62–65].
Oseltamivir is easy to take because it uses the oral route as a capsule or syrup,
so it is preferred for both pediatric and adult patients. In contrast, the two
inhalation agents, zanamivir and laninamivir, are mainly prescribed for the
teenage group. The prescription of the inhaled NAIs for children under 10 years
old is expected to be lower due to difficulty of successful drug inhalation in this
age group.
Laninamivir is a long-acting drug, and the treatment is completed in a single
inhalation [47]. Due to its convenience, the sales of this drug are increasing year
by year. Patients over 20 years old account for 62 % of laninamivir among all
age groups. This shows that laninamivir is the preferred drug for adults and
elderly (Fig. 1). In contrast, zanamivir is prescribed less frequently in patients
over 20 years of age (32 %) because it requires multiple inhalations, twice daily
for 5 days, which is less convenient for busy, working adults. Peramivir is
administered via drip infusion, and it approximately accounts for 3 % of
prescriptions among the four NAIs. Although peramivir is allowed to be used in
outpatients with mild illness [48], there is an ethical dispute about intravenous
(IV) administration for outpatients because a similar clinical effect is expected
with the rest of three NAIs requiring less invasive administration. Thus, the









































































Fig. 1. Estimated number of prescriptions for neuraminidase inhibitors (NAIs), oseltamivir, zanamivir, laninamivir, and peramivir,
and age distribution of patients who received NAIs in Japan. a Estimated number of prescriptions of NAIs during four influenza
seasons from 2011/12 to 2014/2015. b Age distribution during single season of 2014/2015 of patients who received NAIs
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patients, the elderly, and vomiting patients for whom oral intake is not feasible
at outpatient clinics.
Suspension of Oseltamivir Prescription to Teenagers
The suspension of oseltamivir for teenagers goes back to the incidence in 2007.
In February 2007, two Japanese junior high students who were receiving
oseltamivir for the treatment of influenza jumped from buildings and died
[59•]. Oseltamivir was suspected to be the cause of the incidence, although a
causal relationship between the treatment and incidents was not confirmed. In
response to these events, the Dear Healthcare Professional Letters of Emergent
Safety Communications (the Yellow Letter) was issued in March 2007 ordering
clinicians to suspend the prescription of oseltamivir in influenza patients aged
10–19 years of age [11, 59•, 60].
Immediately after the announcement, the use of oseltamivir for 10–19 years
age group dropped dramatically by 63.2 % [11], an indication of the significant
impact of the governmental action. Later, delirious behaviors were also reported
in patients receiving other NAIs [6, 59•, 66]. However, abnormal behaviors are
generally observed during the early stage of influenza illness, within 48 h after the
onset of illness [6]. This triggered investigations focused on studying the rela-
tionship between abnormal behaviors and oseltamivir or other NAI use in Japan.
Currently, it is generally accepted that there is no causal relationship between
oseltamivir or other NAI intake and abnormal behavior [6, 59•, 66, 67]. Yet, the
government restriction on oseltamivir use in teenagers has not been lifted (Fig. 1).
Laninamivir
Laninamivir (laninamivir octanonate, CS-8958) is currently only licensed in
Japan. The drug can be used for outpatients as well as hospitalized patients if
they can inhale the drug.
Laninamivir exhibits long-lasting neuraminidase inhibitory activity against
influenza A and B viruses, including oseltamivir-resistant viruses [68]. The drug
is retained in the respiratory tract for up to 6 days after a single inhalation [69,
70]. After the licensure, it is generally observed that laninamivir is as equally
effective as the other three NAIs against influenza A(H1N1)pdm09, A(H3N2),
and B to children and adults [71–75].
Owing to its single dose regimen, laninamivir’s sales exceeded those of
oseltamivir becoming the top-selling NAI in Japan during the 2014–2015
season (Fig. 1). Of note, the convenience of laninamivir’s single inhaled ad-
ministration could also be a disadvantage if the patient fails to inhale the dose
properly, which is often the case in children younger than 10 years old. There-
fore, the medical staff or pharmacists need to observe young children and assess
whether they can inhale [76]. A special training device making a whistling
sound is distributed free of charge from the manufacturer [76].
In Japan, laninamivir is approved for prophylaxis of influenza. Initial ran-
domized double controlled trial showed that relative risk reductions in sec-
ondary family infections were 77.0% for those given 20mg of laninamivir once
daily for 2 days and 78.1 % for those on 3-day regimen compared to the
placebo [77]. Based on these findings, laninamivir was approved for prophy-
laxis at a dose of 20 mg for two successive days for patients ≥10 years old
(Table 1). A recent randomized double-blind controlled trial demonstrated the
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effectiveness of single 40 mg laninamivir inhalation in post-exposure prophy-
laxis against influenza in adults [78•]. As of 28 August 2016, in a modified
prophylaxis regimen, but the same as treatment course, a single inhalation of 40
mg for children aged ≥10 years and adults and one inhalation of 20 mg for
children G10 years were added together with separated 2-day doses previously
applied (press release from Daiichi Sankyo is available at http://www.
daiichisankyo.co.jp/news/detail/006494.html, Japanese only).
Peramivir
Peramivir is an IV NAI that has been only approved for the treatment (but not
prophylaxis) of influenza in Japan since 2010 [5, 6, 79]. In the USA, the drug
was temporarily approved on November 19, 2009 by Emergency Use Authori-
zation (EUA) by the Commissioner of the Food and Drug Administration [80].
Its use has been limited to hospitalized patients with laboratory confirmed
influenza A(H1N1)pdm09 infection who did not respond to oral or inhaled
antiviral therapy [81]. In 2015, peramivir was fully licensed by the Food and
Drug Administration (FDA) in the USA [82]. In South Korea, peramivir has also
been available in patients with pandemic A(H1N1)pdm09 virus from No-
vember 2009 and has been authorized for sale since August 2010 [83]. The drug
was also used in China for treatment of severe human infections caused by
influenza A(H7N9) in 2013 [84].
Clinical trials in Japan demonstrated that 300 and 600 mg IV administration
of peramivir significantly reduced the time to the alleviation of symptoms
compared to placebo [85]. A phase III study in Korea, Japan, and Taiwan also
showed that the time to the alleviation of symptoms upon a single 300 or 600mg
IV peramivir dose was comparable to orally administrated oseltamivir [86].
Peramivir is approved for children at 10 mg/kg (600 mg maximum dose)
[87]. In high-risk patients, the use of multiple peramivir doses is also licensed in
Japan [61]. In contrast, in the USA, peramivir is only approved for acute un-
complicated influenza in patients 18 years and older who have been symptom-
atic for no more than 2 days [5].
Peramivir is approved in Japan for ambulatory patients without complications,
but the drug is not prescribed as frequently as oseltamivir, zanamivir, and
laninamivir. The estimated prescription rate of peramivir in Japan was around
200,000 doses in the recent four seasons from 2011 to 2015, which is almost one
tenth of other three NAIs (Fig. 1). Peramivir is mainly administered in adults and
elderly (76 %) (Fig. 1), who are admitted to hospital and able to tolerate intrave-
nous administration. Limited observational studies are available for peramivir after
licensure due to the relatively lowprescription rate compared to the otherNAIs [71,
72, 74, 88–91].
Ambulatory children infected with influenza A(H1N1)pdm09 [72] or
A(H3N2) [71] had faster alleviation of fever with peramivir compared to the other
NAIs. Adult patients diagnosed with influenza A and B also reported faster allevi-
ation of fever by peramivir compared to zanamivir and oseltamivir [74]. Other
studies have reported a similar level of effectiveness of peramivir compared to the
other three NAIs in ambulatory adults and children with confirmed influenza A or
B infections [88, 89]. Sato et al. reported that fever duration after a single IV dose of
peramivir did not differ between influenza A- and B-infected patients, but the viral
load decreased faster in the former group [90]. For hospitalized patients, there were
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no significant differences between the peramivir and oseltamivir groups with
respect to the time to fever alleviation [91].
One of the important virological issues regarding peramivir treatment is the
emergence of drug resistance. Themost commonly detected H274Y (H275Y in N1
numbering) mutation in the NA gene confers cross-resistance to oseltamivir and
peramivir [41, 92, 93]. Only one report is available at the moment regarding the
efficacy of peramivir treatment against H275Y mutant A(H1N1)pdm09 virus.
Kakuya et al. demonstrated in a small number of pediatric patients that oseltamivir
and peramivir can retain some clinical effectiveness against the H275Y mutant
virus, in a community outbreak in Hokkaido, Japan during the 2013–2014 season
[94]. To retain the optimal concentration inblood and the upper respiratory tract in
these children, two IV peramivir doses per day (5 or 10 mg/kg at every 12 h) are
preferable based on the PK/PD dynamic models [90]. This course does not follow
the guidelines in Japan, so clinicians need to obtain an informed consent from the
patient prior to initiating the treatment. While most of hospitals possess a stock of
peramivir, it is still less frequently used compared to other NAIs, makes observa-
tional studies difficult. Therefore, multi-center observational studies are needed to
more accurately evaluate the efficacy of peramivir in severely ill patients.
Novel Anti-influenza Drugs in Japan
Favipiravir, T-705, is a selective inhibitor of the RNA-dependent RNA polymerase
of influenza virus and is also reported to inhibit a broad range of other RNAviruses
[95–97]. Additionally, since it does not target the NA, it is effective against NAI-
resistant influenza viruses [98]. A phase III clinical trial of favipiravir, a double-
blind, randomized study comparing it against oseltamivir has been conducted in
Japan since 2009 [99]. Favipiravir was reported to show non-inferiority compared
to oseltamivir [7], but the results have not yet been published in the international
peer-reviewed literature. Although favipiravir has been approved in Japan since
2014, its use is restricted to occasionswhen the government issues a special permit,
such as in the case of infection with a new influenza subtype or when an influenza
virus with reduced effectiveness to the other licensed NAIs is observed [9].
Teratogenicity and embryotoxicity in animal experiments has also been ob-
served with favipiravir, which restricted its use for the treatment of influenza in
everyday practice [7, 9]. However, the animalmodel demonstrated that favipiravir
effectively protects mice from lethal infection with oseltamivir-sensitive or
oseltamivir-resistant highly pathogenic H5N1 viruses [100]. In addition, the drug
has been shown to be a promising treatment for Ebola virus infections [9, 101].
Therefore, the drug can be useful in the treatment of some severe viral infections.
Another new class of anti-influenzadrug is currently in clinical trials in Japan. The
drug, S-033188, is a novel RNA polymerase inhibitor and cap-dependent endonu-
clease inhibitor developed by Shionogi Pharmaceutical Co., Ltd. [102]. Phase II
clinical trials began in October 2015 and were completed in 2016. Phase III clinical
trials inmultiple countries are planned to commence during the 2016/2017 season.
Summary
In summary, the approach to influenza in terms of clinical management and
public health surveillance in Japan exhibits several novel features. This has
driven innovative antiviral drug development in the country, which has benefit-
ed other countries in the form of alternative drug therapies for the treatment of
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this ever-changing virus. The extensive and large-scale surveillance of influenza
and ILI in Japan also encouraged the high consumption of anti-influenza drugs
raising concerns about its potential to select resistant viruses.
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